Previous Close | 2.1200 |
Open | 2.1700 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 2.1000 - 2.3292 |
52 Week Range | 2.0900 - 42.4000 |
Volume | |
Avg. Volume | 88,740 |
Market Cap | 4.222M |
Beta (5Y Monthly) | -0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 America
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that through its collaboration agreement with a large network of integrated, community-based oncology practices, the Company has added multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) in combination with Genentech's Tecentriq® (at
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing the Company's non-viral Oncoprex® Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (NSCLC) in a humanized mouse model.